P17.83 OUTCOMES OF RECURRENT GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB AT A TERTIARY CARE CENTER

BACKGROUND: Bevacizumab is FDA approved for use in recurrent glioblastoma (rGBM). There is limited information on outcomes of rGBM treated with bevacizumab at tertiary care hospitals. We evaluated the progression-free survival (PFS) and overall survival (OS) in rGBM patients treated with bevacizumab...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Stevens, G.H.J., Sakruti, S., Griffin, S., Peereboom, D., Ahluwalia, M.S.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2014
Materias:
Poster Presentations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4185786/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou174.412
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares